Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
NORCROSS, Ga., Jan. 28, 2016 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company’s president, chief executive officer and chief medical officer will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.
The BIO CEO presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
https://www.bio.org/events/conferences/bio-ceo-investor-conference
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. It has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to its investment banking activity. http://www.sourcegrp.com/
Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
LHA
Kim Golodetz
(212) 838-3777
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
